

# Aenco Ecosystem

Innovation | Impactful | Integrity

Global HealthTech Blockchain  
Financial Solutions Platform

# Disclaimer

This presentation is for information purposes only and may be subject to change.

Neither Aenco nor Aeneas (the "Company") cannot guarantee the accuracy of the statements made or conclusions reached in this presentation. The Company does not make and expressly disclaims all representations and warranties (whether express or implied by statute or otherwise) whatsoever, including but not limited to: any representations or warranties relating to merchantability, fitness for a particular purpose, description, suitability or non-infringement; that the contents of this document are accurate and free from any errors; and that such contents do not infringe any third party rights.

The Company shall have no liability or damages of any kind arising out of the use, reference to or reliance on the contents of this presentation. This presentation may contain references to third-party data and industry publications. As far as the Company is aware, the information reproduced in this presentation is accurate and that its estimates and assumptions are reasonable. However, there are no assurances as to the accuracy or completeness of this information. Although information and data reproduced in this presentation are believed to have been obtained from reliable sources, we have not independently verified any of the information or data from third party sources referred to in this presentation or ascertained the underlying assumptions relied upon by such sources. As of the date of publication of this presentation, AEN Tokens have none known potential uses outside of the Aeneas Ecosystem and are not permitted to be sold or otherwise traded on third-party exchanges.

This presentation does not constitute advice nor a recommendation by the Company, its officers, directors, manager, employees, agents, advisors, or consultants, or any other person to any recipient of this paper on the merits of participation in the Aenco Token Sale. Participation in the Aenco Token Sale carries substantial risk that could lead to a loss of all or a substantial portion of funds contributed. No promises of future performance or value are or will be made with respect to Tokens, including no promise of inherent value, no promise of continuing payments, and no guarantee that AEN Tokens will hold any particular value. Unless prospective participants fully understand and accept the nature of the Company's proposed business and the potential risks inherent in AEN Tokens, they should not participate in the Aenco Token Sale.

AEN Tokens are not being structured or sold as securities. AEN Tokens are not a participation in the Company and AEN Tokens hold no rights in the Company. AEN Tokens are sold with an intended future functionality on the platform to be developed by the Company and all proceeds received during the Token Sale may be spent freely, by the Company on the development of its business and platform. This presentation does not constitute a prospectus or offering document and is not an offer to sell, nor the solicitation of an offer to buy any investment or financial instrument in any jurisdiction. AEN Tokens should not be acquired for speculative or investment purposes with the expectation of making an investment return. No regulatory authority has examined or approved any of the information set out in this presentation. No such action has been or will be taken under the laws, regulatory requirements or rules of any jurisdiction. The publication, distribution, or dissemination of this presentation does not imply that applicable laws, regulatory requirements or rules have been complied with. AEN Tokens could be impacted by regulatory action, including potential restrictions on the ownership, use, or possession of such tokens. Regulators or other competent authorities may demand that AEN Tokens revises the mechanics and functionality of AEN Tokens to comply with regulatory requirements or other governmental or business obligations. Nevertheless, The Company believe they have taken commercially reasonable steps to ensure that its planned mechanics are proper and in compliance with currently considered regulations. The Company is in the process of undertaking further legal and regulatory analysis of the intended functionality and mechanics of AEN Tokens. Following the conclusion of this analysis, we may be required to amend the intended functionality of AEN Tokens in order to ensure compliance with any legal or regulatory obligations that apply to us. We shall update this presentation and publish a notice on our website in the event that any changes are made to the AEN Token functionality.

## CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements or information (collectively "forward-looking statements") that relate to the Company's current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "anticipate", "aim", "estimate", "intend", "plan", "seek", "believe", "potential", "continue", "is/are likely to" or the negative of these terms, or other similar expressions intended to identify forward-looking statements. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, financial needs, or the results of the token sale or the value or price stability of AEN Tokens.

In addition to statements relating to the matters set out here, this presentation contains forward-looking statements related to the Company's proposed operating model. The model speaks to its objectives only, and is not a forecast, projection or prediction of future results of operations. Forward-looking statements are based on certain assumptions and analysis made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. Although the forward-looking statements contained in this presentation are based upon what the Company believes are reasonable assumptions, these risks, uncertainties, assumptions, and other factors could cause the Company's actual results, performance, achievements, and experience to differ materially from its expectations which are expressed, implied, or perceived in forward-looking statements. Given such risks, prospective participants in this token sale should not place undue reliance on these forward-looking statements.



# Table of Contents

|   | Page No. |
|---|----------|
| Aenco and AEN Token   | 4        |
| How it Works? Our Ecosystem by HealthTech Partners, Innovators, and Users                       | 5        |
| What is Aenco's Vision?   | 6        |
| The Existing Challenges to HealthTech   | 7        |
| The Opportunities: A Pressing Need for Medical Innovation                                       | 8        |
| The Landscape:  |          |
| ▪ Medical Research Funding Channels   | 9        |
| ▪ ICOs versus Traditional IPOs  | 10       |
| The Structure – Legal and Regulatory Framework  | 11       |
| Our ICO Integrity Program - Building a Credible Standard of ICO Best Practices                  | 12       |
| Aenco "HealthTech": Core IB Solutions   | 13       |
| ICO Sponsoring as a Service   | 14 – 15  |
| Subscription Infographic for Aenco sponsored ICOs   | 16       |
| Infographic for AENX: HealthTech Centric Trading Exchange                                       | 17       |
| HealthTech Technology: Roll out, 1 <sup>st</sup> – 3 <sup>rd</sup> generation core technologies | 18 – 20  |
| Prime Brokerage Service   | 21       |
| Infographic for Aenco Prime Solutions   | 22       |
| The AEN Token   |          |
| ▪ Ecosystem Benefits for AEN Token Holders: Financial Utility & Medical Utility                 | 23 – 24  |
| ▪ More Participation in the Ecosystem   | 25       |
| Ecosystem History and the Roadmap   | 26       |
| Indicative ICO Offering Details   | 27       |
| Indicative Token Supply and Allocations   | 28       |
| Use of Proceeds   | 29       |
| The Team / Strategic Advisors and Partners  | 30 – 37  |
| Contacts  | 38       |



# Aenco and AEN Token

## “First Blockchain-based Healthcare Technology Financial Solutions Platform”

1. Aenco is the world's **FIRST Blockchain based Healthcare Technology Financial Solutions Platform**, that leverages healthtech with investment banking (“IB”) and prime brokerage solutions under one umbrella.
2. Aenco is a **"one stop shop"** for the delivery of cutting edge IB and prime solutions for the HealthTech industry, as well as a research and collaboration hub for healthcare blockchain companies and projects.
3. Aenco is combining its **core financial ecosystem** with the wider healthcare technology community, through the AEN token, as the key ecosystem building block and extensions.
4. Aenco is supported by the group's evolving **regulated infrastructure and presence in major jurisdictions** including Europe, Hong Kong, and the United States, through which Aenco will effectively deliver its solutions, generating a significant and rapidly evolving ecosystem.






# How It Works?

- Our Ecosystem by HealthTech Partners, Innovators, and Users

Global Community  
(excl. geofenced jurisdictions)

**Users  
&  
Participants**



Enjoy:

- 1) Automated Aenco platform membership
- 2) Priority access to ecosystem opportunities and utility
- 3) Community rewards and bounty programs
- 4) Access and reduced fees across platform solutions
- 5) B2B and B2C access to wholesale platform
- 6) Secondary market liquidity

**Note:** Each business component of Aenco shall be operated through a relevant licensed entity that is located in a jurisdiction approving its related activities.

Aenco Global HealthTech  
Financial Solutions

**Aenco Ecosystem & Applications**

## Aenco IB Solutions

- ❖ Aenco ICO Gateway and Portal: ICO Integrity Program
- ❖ AEN Connect: Aenco smart wallet and Wealth App functionalities
- ❖ AENX HealthTech Trading Exchange
- ❖ Aenco Data Analytics and ongoing research coverage

## Aenco Prime Solutions

- ❖ Aenco Decentralized Prime Brokerage Platform
- ❖ Cross-asset collateralized lending and borrowing
- ❖ Financing pools interfacing major fiat and major digital assets

## Aenco SmartCap Solutions

- ❖ Aenco Core technology-driven smart capital Solutions
- ❖ Aenco alternative financing platform

Use AEN tokens

HealthTech Partners and  
Future Sponsored Projects

### Therapeutics



Infectious Diseases



Gastroenterology



Neurology



Natural Health



Oncology



Others

Share utility

Earn access to  
HealthTech  
Financial  
Solutions

### Medical Infrastructure



Labs



Robotic Surgery  
Equipment



Clinics

Share utility

Earn access to  
HealthTech  
Financial  
Solutions

### Medical Data Analytics



Clinical Pathway  
Data Encryption



Big-Data  
Research



Artificial  
Intelligence

Share utility

Earn access to  
HealthTech  
Financial  
Solutions



# What is Aenco's Vision?

- ❖ To be first and global **“HealthTech” blockchain based financial solutions platform** leveraging on the strengths of blockchain and decentralized applications.
- ❖ To **empower emerging healthcare companies** with fintech based solutions, so that they can focus on generating medical solutions for the world.
- ❖ To build an ecosystem encompassing fintech financial solutions specialized in the health technology sector, with its network activity and services fueled by the **“AEN”** utility token.
- ❖ To be a major player contributing to a new era of trust, openness, and global acceptance for the **crypto industry**.
- ❖ To conduct a successful token offering via a targeted **initial coin offering (“ICO”) in 2018**, to galvanize the development cycle of the Aenco platform.


*“We empower HealthTech innovators financially and connect the community with medical utility”*

Aenco Vision Pillars



# The Existing Challenges to HealthTech

- ❖ The pairing of **sound Science + robust Finance** is essential for medical and health technology innovation.
- ❖ Yet steady and impactful **sources of funding** of emerging biotech and medtech companies are intrinsically difficult. i.e. Very capital intensive!
- ❖ Today's landscape for **capital raising channels** is traditionally dominated only by the largest players such as global investment banks and venture capital.
- ❖ **High entry-barriers and hurdles can prove to be burdensome** for growth companies seeking funding in the form of significantly high fees and opaque access.
- ❖ Young companies requiring **institutional grade, one-stop-shop investment banking services** such as financing, underwriting, settlement, custodial, research, and trading services, have little options if they fail to "join the club".
- ❖ Meanwhile, there is new age development in **digital finance, blockchain applications**, and growth in circulation of digital assets are opening new financing channels such as Initial Coin Offerings ("ICOs").
- ❖ Yet society continues to lack a credible, **globally accredited "standard" for ICO best practice**, cultivating skepticism and distrust towards a financing channel that possesses utmost potential and impact.




- **Financing channels**
- **Business and value validation**
- **Legitimizing new age process**
- **Security, transparency, and permanence**




# The Opportunities:

- A Pressing Need for Sustainable Medical Innovation


- ❖ Global unmet healthcare needs and ageing demographics, presents both the **need** and **opportunities** for medical entrepreneurialism to develop solutions that have deep societal impact.



**Exhibit 1:** Young children and older people (% of global population): 1950-2050 (i)



**Exhibit 2:** Alzheimer's Disease ("AD") Cost of Care versus Research Funding 2010 – 2050 (Example of global unmet medical need) (ii)



Sources: (i) World Population Prospects: The 2010 Revision, United Nations; (ii) Alzheimer's Study Group / The Alzheimer's Association





# The Landscape:

## - Medical Research Funding Channels

- ❖ Taking traditional funding channels in the U.S. as an example for **medical innovation and entrepreneurialism**: We see new age financing mechanisms emerging as a significant and impactful source of funding.



- Heavy reliance on friends, family, grants, government subsidy, and sponsored research
- Little institutional financing support
- Pressure to source capital detracts from critical research process
- Dilution of equity ownership
- Pressured to create investment exit opportunity (e.g. IPO)
- Non-trivial VC expectations: Near term sales generation, multibillion dollar market sizes etc.
- High entry barriers in the form of fees and access
- Are you able to 'join the club' for institutional grade investment banking services?
- Burdensome scrutiny and regulation



# The Landscape: “ICOs” vs traditional IPOs

## - An Increasingly Impactful Form of Empowerment


- ❖ Data for 2017 with respect to the size of capital raised via traditional capital markets activity such as initial public offerings (“IPO”) is coming in at **USD \$189 billion globally**<sup>1</sup> (1,624 IPOs).
- ❖ In comparison, based on 2017 available figures, the cumulative size of initial coin offerings (“ICO”) and similar blockchain based financing activities since 2014 amounts to USD \$2.4 billion, whereby more than **USD \$2.0 billion was raised in 2017 alone**<sup>2</sup>!
- ❖ Therefore, blockchain based financing represents **c. 1.1% of capital markets** and financing activities globally; and is a **hugely untapped** form of funding for a broad range of innovative startup companies requiring capital.
- ❖ ICOs will soon develop as a **mainstream channel** for funding through an increasingly robust regulatory framework.
- ❖ **Aenco and the Aeneas ecosystem** seeks to be at the forefront of this sensational development as a major inflection point has come!

Sources:

1. EY Global IPO trends: 2014-2017


2. Coindesk ICO tracker

**Exhibit 3: Annual and cumulative capital raised via ICO**



Source: Coindesk ICO tracker

**Exhibit 4: Annual capital raised and number of IPOs**




Source: EY Global IPO trends; 2014-2017



# Our Structure:


## - Legal and Regulatory Framework

- ❖ Our ecosystem leverages off the long-standing business infrastructure of Aeneas' traditional financial services platform, as well as newly developing business segments; to facilitate the delivery of our Global HealthTech Financial Solutions within the context of **accredited regulatory frameworks** across major global markets.



# Our ICO Integrity Program


- Building a Credible Standard of ICO Best Practices





# Aenco “HealthTech”: Core IB Solutions

- ❖ A global **full-service HealthTech Investment Bank (“IB”)** employing a decentralized blockchain based financial ecosystem that amalgamates traditional and modern methods of capital market services.
- ❖ Powered by an in-house developed **core utility token AEN** as a medium of exchange, tradable and exchangeable with accepted major crypto and fiat currencies.



## ICO and Distribution

- Marketing platform for medical ICOs
- Audience based marketing and advisory
- Token classification
- Subscriber audience
- Global distribution

## Sponsorship and Liquidity Provider

- Hard sponsorship and ‘best effort basis’ sponsorship service
- Anchor investment to medical ICOs
- Initial valuation validation
- Liquidity provider for client tokens

## Custodial and Escrow Services

- Escrow services within ICO process to enhance issuer credibility, and confidence of token buyer
- Secure digital asset wallet and safe-keeping infrastructure

## Legal, Financial, and Business Due Diligence

- In-depth screening of client business case before ICO launch
- Regulatory landscape
- Financial due diligence
- Verification of targeted product market size and product segmentation

## Research Coverage and ICO data analytics

- Ongoing ICO research coverage
- Periodic reviews of issuer developments and milestone achievements
- Maintain and grow secondary market awareness of client tokens

## Exchange Trading Platform (“AENX”)

- AENX crypto exchange to facilitate trade orders and secondary market liquidity
- Enable trading and clearing across AEN pairs with major crypto and fiat currencies
- AENX Professional for accredited investors



# ICO Sponsoring as a Service - Structure

Exhibit 5:

## Traditional IPO Underwriting Structure





Exhibit 6:

## HealthTech ICO Sponsoring Structure



# ing as a Service - Process

### Exhibit 7:


## Traditional IPO Underwriting Process

```
graph TD; A[Firm to issue new securities] --> B[Investment Bankers ("IB") and firm agree on type and price of security]; B --> C[Firm prepares prospectus with help of IB]; C --> D[Prospectus is distributed to brokerage network; pre-issue sales solicited]; D --> E[Regulator approval received; Finalized prospectus is distributed]; E --> F[Securities are bought by IB and resold to the public]; F --> A; C --> G[Regulator (e.g. SEC) reviews prospectus]; G --> E;
```

The flowchart illustrates the Traditional IPO Underwriting Process. It begins with a firm deciding to issue new securities. This leads to the firm and investment bankers (IB) agreeing on the type and price of the security. The firm then prepares a prospectus with the help of the IB. The prospectus is distributed to a brokerage network, and pre-issue sales are solicited. The regulator (e.g., SEC) reviews the prospectus. Once regulator approval is received, the finalized prospectus is distributed. Finally, the securities are bought by the IB and resold to the public. The process is a closed loop, as the funds from the sale are sent back to the firm to issue the securities.

**\$ / €**  
*Fiat funds to issuing firm*

## Traditional IPO Underwriting Process




### Exhibit 8:

## HealthTech ICO Sponsoring Process

```
graph TD; A[Issuer to offer new tokens] --> B[Aenco performs legal, financial, business due diligence on Issuer]; B --> C[Issuer finalizes white paper with help of Aenco]; C --> D[Aenco reviews whitepaper]; D --> E[Aenco advises on token sale marketing and distribution strategy]; E --> F[Whitepaper circulated on Aenco ICO gateway and portal]; F --> G[For syndicated sponsorship, client tokens are bought by Aenco and resold to the public on a preemptive basis]; G --> H[Aenco holds subscriber funds in as escrow and released based on ICO terms]; H --> I[Aenco provides liquidity in AENX and other decentralized exchanges for client tokens and AEN tokens]; I -- "AEN / fiat circulation" --> A; I -- "AEN / $ AEN / €" --> A; I -- "AEN subscription proceeds" --> A;
```


The flowchart illustrates the HealthTech ICO Sponsoring Process, starting with the Issuer offering new tokens. Aenco performs legal, financial, and business due diligence on the Issuer. The Issuer finalizes the white paper with the help of Aenco, which then reviews the whitepaper. Aenco advises on the token sale marketing and distribution strategy. The whitepaper is circulated on the Aenco ICO gateway and portal. For syndicated sponsorship, client tokens are bought by Aenco and resold to the public on a preemptive basis. Aenco holds subscriber funds in escrow and releases them based on ICO terms. Finally, Aenco provides liquidity in AENX and other decentralized exchanges for client tokens and AEN tokens. The process concludes with AEN / fiat circulation and AEN / \$ AEN / €.

## HealthTech ICO Sponsoring Process



# Subscription Infographic for Aenco Sponsored ICOs

**Exhibit 9:** What are the ecosystem activities for Aenco sponsored ICO subscriptions?






# Infographic for AENX:

## - HealthTech Centric Trading Exchange


- ❖ AENX crypto exchange to facilitate trade orders and secondary market liquidity services;
- ❖ To enable trading and clearing across AEN pairs with major crypto and fiat currencies.

**Exhibit 10: Transacting on AENX**



# “HealthTech”: Technology Rollout

- ❖ Underlying technological advancements powering Aenco's “Global HealthTech Financial Solutions” are planned **to roll out in three broad phases**, or generational leaps.



# “HealthTech”: 1<sup>st</sup> and 2<sup>nd</sup> Generation Core Technologies

- ❖ **1<sup>st</sup> generation technology: AEN Connect** smart wallet to be rolled out post ICO to ensure efficient launch of tokens and safe storage of the wallet.
- ❖ **2<sup>nd</sup> generation technology:** ramp up to move full throttle post-ICO phase with new resources channeled towards the development of underlying “HealthTech” platform technologies.



# “HealthTech”: 3<sup>rd</sup> Generation Core Technology

- ❖ **3<sup>rd</sup> generation technology:** Aenco decentralized prime brokerage platform that empowers clients and token holders with access to execution, financing, settlement, and custodial services for traditional asset classes, structured products, and digital assets.

← 3<sup>rd</sup> Generation →



## Cross –asset collateralized loans and borrowing

- Execution, financing, and settlements for both traditional asset classes and digital assets
- Crypto collateralized stock borrowing and lending



## Regulatory reporting protocols

- Automated reporting with adherence to regulatory standards for both exchange traded and OTC requirements
- Experienced regulation tech team to support compliance



## Full service user friendly digital interface

- For client management of large portfolio executions, order flows, and settlement



## Client custodial and asset segregation services

- Custodial services of client assets and compliance with segregation of assets regulation



## Financing pools using both major fiat and crypto currencies

- Source financing through a decentralized financing pool
- Borrowers and liquidity providers have transparent access to collateral pools



## Margining and clearing system

- System handling intraday and daily margin monitoring requirements for the margining of both single and aggregated positions



## Over-the-counter (“OTC”) and on-exchange settlements

- Access to both OTC and exchange settlement capabilities for both traditional assets and crypto currencies





# Prime Brokerage Service

Exhibit 11:

## Traditional Prime Brokerage Structure






Exhibit 12:

## HealthTech Prime Brokerage Structure



# Infographic for Aenco Prime Solutions

**Exhibit 13:** What are examples of collateralized lending activity on Aenco's prime brokerage platform?



# Ecosystem Benefits for AEN Token Holders?

- Indicative financial utility benefits and access within the Aenco Ecosystem

## Aenco IB Solutions

### Priority Access To Investment Opportunities

- To all pipeline Aenco vetted token offerings;
- Access private Pre-ICO allocations.

### Discounted Participation

- In Aenco sponsored HealthTech ICO deals;
- Entitled AEN holders enjoy significant discount in Pre-ICO private offerings.

### Enhanced Security Settings for Custodial Services



### Access to ICO Research Portal and Big-Data Analytics

- Free research access to ICO coverage universe;
- Top tier access to ICO platform data analytics:
  - Subscriber data to potential issuers;
  - ICO/Issuer data to potential subscribers



### AEN Token Holders Membership Benefits

- Proof of stake membership
- Use AEN as medium of exchange

## Aenco Exchange Solutions

### Reduced Platform Fees

- Exchange fees / Transaction fees;

### Free "Airdrops" on Aeneas Sponsored ICO Tokens

### Enhanced Flexibility

- Higher deposit and withdrawal thresholds.

|  | AEN                                   | Others      |
|--|---------------------------------------|-------------|
| Exchange fees (%) – maker / taker trades | Free to 15% discount on standard fees | 0.10 / 0.25 |

## Aenco Prime and SmartCap Solutions

### Reduced fees and tariffs on SmartCap financial services

|                          | AEN                                   | Others               |
|--------------------------|---------------------------------------|----------------------|
| Account opening fees     | Free to 15% discount on standard fees | X                    |
| Remittance / FX fees     |                                       | flat rate            |
| Trade services           |                                       | e.g. 1/8% min \$12.5 |
| Autopay services         |                                       | 2% p.a. annual fee   |
| Asset management fees    |                                       |                      |
| Commercial card services |                                       |                      |

### Alternative Investment



### Receivables Financing

### Bridge Financing

### Collateralized Lending

### Attractive Financing Rates (%) per annum

|                     | Crypto                                | Securities   |
|---------------------|---------------------------------------|--------------|
| Entitled AEN Holder | Up to [25]% premium on standard rates |              |
| Others:             | [3]% - [15]%                          | [3]% - [10]% |

### Collateralized Lending

- Preferential rates for AEN
- Borrow/Lend AEN against major crypto

| Proof of Stake          | Tiered approach |
|-------------------------|-----------------|
| Increased LTV ratio (%) |                 |
| Entitled AEN Holder     | 30-80           |
| Others                  | 20-60           |

### Decreased interest expense on borrowing

| Proof of Stake         | Tiered approach      |
|------------------------|----------------------|
| Interest rate (%) p.a. |                      |
| Entitled AEN Holder    | Up to [25]% discount |
| Others                 | 4.0                  |

### Increased interest income on deposits


| Proof of Stake         | Tiered approach     |
|------------------------|---------------------|
| Interest rate (%) p.a. |                     |
| Entitled AEN Holder    | Up to [30]% premium |
| Others                 | 0.5% - 1%           |

\* Fees and rates are indicative and subject to prevailing 'market rates' during the course of normal business operations; AEN benefits are reasonably estimated with reference to standard fees and rates offered. All figures quoted above are indicative only for illustration purposes and will be subject to change during implementation and roll out.



# Ecosystem Benefits for AEN Token Holders?

- Example of medical utility benefits from HealthTech partners



\* Described are examples of medical utility benefits which can be offered from existing HealthTech partners of Aenco. Going forward it is Aenco's primary role to continue identifying, sponsoring, and empowering credible HealthTech partners with potential to provide invaluable medical solutions and utility to the global community.





# The AEN Token:

## - More Participation in the Ecosystem

Further snapshot of being holders of AEN will enjoy the following membership benefits in the Aeneas ecosystem. The below list is not exhaustive.


- ❖ **Automated Platform membership** to all of Aenco's "HealthTech" Blockchain Financial Solutions: (i) Aenco IB Solutions; (ii) Aenco Prime Solutions; and (iii) Aenco's wider regulated infrastructure and services;
- ❖ **Priority and pre-emptive membership exclusive access** to pipeline opportunities (e.g. Private Pre-ICO allocations) and high-quality, diligently screened token offerings, based on AEN stake by existing holder and associated research coverage;
- ❖ **"Lease" AEN tokens and sponsored tokens** into the Aenco solutions network to support ongoing transactions;
- ❖ **Community Rewards and Bounty Programs** for our holders, administrators, partners to help drive the growth of our AEN ecosystem;
- ❖ **Automated access to collaboration opportunities** with other sponsored health care technology and blockchain projects and **reward programs** for the support of the growth of the ecosystem for such projects;
- ❖ **Eligible access to and reduced fees** for IB Solutions Exchange platform to transact in AEN / Aenco sponsored tokens / major crypto / fiat / other eligible trading pairs;
- ❖ **Collateral financing opportunities at discount benefits** based on, for example, tiered AEN stake by existing participant;
- ❖ **Eligible for beneficial rates** for participating in Aeneas' products based on tiered AEN stake by existing holder;
- ❖ **B2B and B2C Access to wholesale platform** for our community members to "piggy back" on our solutions and core regulated infrastructure to help grow the ecosystem and facilitate their respective demands.
- ❖ **Secondary Market Liquidity** support provided by the Aenco platform on its own exchange and external partners to facilitate the continuous adoption and dominance of AEN token as the major trading pair in the market.



# Ecosystem History and the Roadmap

- 13 years of history, 24 months forward-looking plan

Exhibit 14:



# Indicative ICO Offering Details

- ❖ A 2018 ICO is planned to fuel the development of Aenco's HealthTech Financial Solutions platform, and the sponsoring / cultivation of existing and new HealthTech partners.
- ❖ Indicative offering terms are depicted below but subjected to more definitive changes.

## Exhibit 15:

|                                |                               |
|--------------------------------|-------------------------------|
| Token Symbol                   | <b>AEN</b>                    |
| Token Name                     | <b>AEN Coin</b>               |
| Token Type                     | <b>ERC223</b>                 |
| USD Price per token at ICO     | <b>0.1</b>                    |
| USD Price per token at Pre-ICO | <b>0.1 + 50% bonus tokens</b> |
| Total Token Supply             | <b>4,000,000,000</b>          |
| Tokens Being Sold              | <b>600,000,000</b>            |

| Allocation           | Tokens  |
|----------------------|---|
| Pre-ICO Sale         | 200,000,000 (5% total supply)                                 |
| Pre-ICO Bonus Scheme | 100,000,000 (+50% bonus)                                      |
| ICO Public Sale      | 400,000,000 (10% total supply)                                |
| ICO Bonus Scheme     | Week 1: +20% bonus<br>Week 2: +10% bonus<br>Week 3: +5% bonus |
| Tokens Unsold        | Allocated to Reserves; See Exhibit 16                         |

|                               |                      |
|-------------------------------|----------------------|
| Soft Cap on Crowdsale (USD)   | <b>\$ 15,000,000</b> |
| Target Cap on Crowdsale (USD) | <b>\$ 60,000,000</b> |
| Accepted Crypto Assets        | <b>BTC, ETH</b>      |



# Indicative Token Supply and Allocations

**Exhibit 16:**

| Token Allocation                          | Intended Use   | Lock-Up Period   | AEN Amount  | Allocation Percentage |
|---|--|--|-------------|-----------------------|
| Token Sale (excl. bonus allocations)      | Covers the Pre-ICO private sale and ICO public sale (excluding bonus tokens allocated).  | <b>Pre-ICO Private Sale:</b><br>Lock-up of 3 months on 50% of tokens;<br>No lock-up on remaining 50%.<br><b>ICO Public Sale:</b> No lock-up.                                     | 600,000,000 | 15%                   |
| Retained by Company and Team              | The team will be allocated tokens as compensation for early involvement and to incentivise continued engagement in the ecosystem.                              | <b>Management:</b> Lock-up of:<br>6 months on 25% of tokens;<br>12 months on 25%;<br>18 months on 25%;<br>24 months on 25%.<br><b>Non-Management:</b> Lock-up of 6 to 12 months. | 884,000,000 | 22%                   |
| Ecosystem Liquidity                       | Provides liquidity measures to support a growing Aeneas ecosystem and services provided through Aenco applications.  | Not Applicable   | 600,000,000 | 15%                   |
| Allocated to Ecosystem Partners / Backers | Token allocation in recognition for their resources and efforts contributed by key partners and supporters towards the Aenco project and Aeneas ecosystem.     | Lock-up of 3 months on 100% of tokens.   | 480,000,000 | 12%                   |
| Reserved for Incentive Programs           | Incentive program for healthtech partners and community referrals in relation to token sale. For example, referral bonuses of 5%/10% on referred ICO proceeds. | Not Applicable   | 480,000,000 | 12%                   |
| Bonus Allocations (on token sale)         | Bonus tokens allocated to early subscribers throughout the Pre-ICO private sale and ICO public sale.   | From <b>Pre-ICO Private Sale:</b><br>Lock-up of 3 months on 50% of tokens;<br>No lock-up on remaining 50%.<br>From <b>ICO Public Sale:</b> No lock-up.                           | 156,000,000 | 4%                    |
| Reserves and token sale costs             | Retained to fuel the development and stability of the Aeneas ecosystem. AEN holders may be able to acquire future releases of AEN from the reserve.            | Not Applicable   | 800,000,000 | 20%                   |

\* Unsold tokens will be allocated reserves

**4,000,000,000**

**100%**






# Use of Proceeds

- ❖ Post-ICO proceeds are to be primarily and efficiently deployed towards core HealthTech services including: (i) Sponsoring HealthTech partners; (ii) Financial solutions servicing; (iii) the development and roll out of core ecosystem technologies, and (iv) platform operations.

**Exhibit 17:**

|                           |   | Soft Cap     |                   | Target Cap   |                   |
|---------------------------|---|--------------|-------------------|--------------|-------------------|
| ICO Proceeds Raised (USD) |   | 15,000,000   |                   | 60,000,000   |                   |
|                           |   | % Allocation | USD               | % Allocation | USD               |
| 1.                        | Sponsorship and Financial Solutions Platform for HealthTech Partners      | 40%          | 6,000,000         | 42%          | 25,200,000        |
| 2.                        | Research, Technology Development and Roll Out, and Collaboration Research | 30%          | 4,500,000         | 28%          | 16,800,000        |
| 3.                        | General Working Capital and Infrastructure Setup Capital Requirements     | 24%          | 3,600,000         | 25%          | 15,000,000        |
| 4.                        | Marketing and Distribution  | 3%           | 450,000           | 3%           | 1,800,000         |
| 5.                        | Legal and Compliance  | 3%           | 450,000           | 2%           | 1,200,000         |
| <b>TOTAL</b>              |   | <b>100%</b>  | <b>15,000,000</b> | <b>100%</b>  | <b>60,000,000</b> |



# The Team (1)

## IAN HUEN

*Co-Founder*



- Over 15 years of global asset management experience;
- Founder and Managing Director of Aeneas Capital;
- Former U.S. Equity research analyst at Janus Capital;
- Financial adviser to sale of Seng Heng Bank to ICBC in 2007;
- Trustee board of Dr Stanley Ho Medical Development Foundation;
- Panelist and speaker at Euromoney, S&P and the Middle East Investment Summit (MEIS 2017);
- MA in Comparative and Public History, The Chinese University of Hong Kong;
- A.B. Economics, Princeton University and CFA Charterholder;
- Financier, calligrapher, and historian.

## DARREN LUI

*Co-Founder*



- Co-Founder of Aptorum Group Limited, a biotech platform.
- Co-Founder of Aeneas Group;
- Former Founder and Director at Varengold Capital, a HK based regulated asset manager and prime broker;
- Former Director at Barclays Capital, Barclays Bank PLC. London, Singapore and New York offices.
- Qualified Chartered Accountant (ICAS) at Ernst & Young LLP(UK).
- CFA Charterholder.
- Associate of Chartered Institute of Securities & Investments.
- First Class Honours BSc in Biochemistry, Imperial College London.

## KENRICK H. FOK

*Chief Financial Officer*



- Multi-asset investment management professional and investor;
- Over 14 years of alternative investment experience spanning across hedge funds, asset managers, and direct investments;
- Former Investment Director and Responsible Officer at Guardian Capital Management;
- Former Equity Portfolio Manager and Responsible Officer at Generali Investments Asia (Generali Group company);
- Former Portfolio Manager and Responsible Officer at MAPS Capital Management (Mirae Asset Financial Group company);
- CFA Charterholder
- Sc. B Engineering, Brown University.

## GEOFFREY TIPTON

*Chief Technology Officer*



- Numerous years of product and software development experience in Asia.
- Blockchain application and digital asset enthusiast.
- Control Engineering and Robotics specialist.
- 3 year tour of duty as a Paramedic in the British Armed Forces.
- Early years in Blackpool working behind the scenes on many theatre stage productions (e.g. John Inman, Tommy Steel, Genesis, Sad Cafe).
- Avid horse rider and motorcyclist.
- Life long member of the Aviation club where flying a Robinson 22 helicopter is the preferred choice of transport.



# The Team (2)

## CHARLES LAU

### *Managing Director*

- Over 17 years experience in financial industry, as senior management in European banks and founder of wealth management company.
- Former Managing Director at Varengold Hong Kong, where its parent company Varengold Bank AG is a German Private Bank listed in Hamburg.
- Former senior management at Credit Suisse Privilege, Credit Suisse Bank, Hong Kong.
- Founder and CEO of MCG Private Wealth, a Private-equity funded wealth management company based in Hong Kong.
- Master of Business Administration graduate with focus on applications of modelling and theories in the financial industry.

## ERICA CHAN

### *Head of Wealth Management*

- Over 15 years of experience in financial industry, as senior management in European banks and wealth management company;
- Head of Wealth Management at Aeneas Group, a technology driven financial services platform based in Hong Kong;
- Former Head of Wealth Management at Varengold Hong Kong, wholly owned by Varengold Bank AG, a German Private Bank listed in Hamburg;
- Former Senior Executive Vice President at Credit Suisse Privilege, Credit Suisse Banking Group;
- BA (Hon) in Public & Social Administration.

## NICK WAN

### *Co-Investment Director*

- Solid knowledge of real estate market dynamics;
- In-depth knowledge of different property asset classes;
- Diverse experience in various areas within real estate industry;
- Wide geographical exposure including Asia, Europe, and the US real estate markets;
- Former investment manager and Responsible Officer at New Century Asset Management Limited (manager of New Century REIT);
- Former investment & asset manager at Invesco Real Estate Investment Asia Pacific Limited, AIG Global Real Estate (Asia) LLC, and Mapletree Logistics Trust Management Limited;
- BBA in Finance and Management Science, Simon Fraser University.

## CALVIN POON

### *Co-Investment Director*

- Over 20 years of experience in real estate investment, development, asset management and project management;
- Diversified real estate experience in commercial, residential and hospitality sectors;
- Senior real estate management positions held in various public and private companies in Hong Kong and U.S. Former Head of Project at Glory Century Limited; Investment Manager at Imperial Pacific International Holdings Limited; and Executive Director at Euro Properties;
- Licensed real estate broker in New York State;
- M.S. in Real Estate Investment and Asset Management, New York University;
- M.S. and B.S. in Civil Engineering, Columbia University.



# The Team (3)

## ALLY CHEUNG

*Head of Community Management*



- Community builder in the blockchain space, bridging the gap between today's reality and tomorrow's possibility with a positive belief and strategic vision;
- Community Manager at Monaco, one of the most successful token sale events to date;
- Business Development Manager at Galileo Platforms, an InsurTech blockchain startup for reinventing the insurance industry;
- Deep enthusiasm in Blockchain technology and the cryptocurrency industry;
- MBA graduate from HKUST Business School and exchange in NYU Stern School of Business, focused on Finance ;
- Avid traveler, music junkie and foodie at hearty.

## DAVID CAREY

*Senior Cloud Engineer*



- Lead in Security Review and hardening of the United Nations back-end systems;
- CTO of Network-box Thailand keeping the country secure;
- Developed online marketing and lottery systems;
- Developer of Web based applications and systems;
- Independent Consultant for Online Streaming solutions;
- Cloud services manager and enabler for various solution Providers;
- Cloud provisioning, monitoring and security hardening.

## MICHELLE AU

*Creative Specialist – UX/UI Designer*



- Over 10 years experience in web, commercial graphic & packaging design;
- Former Packaging Design Supervisor (AD) at Capdase, Hong Kong;
- Former Packaging Design Lecturer at Raffles College of Design and Commerce, Hong Kong;
- Years of experience in independent projects, worked with clients from various industries & platforms;
- B.A. in Digital Media Technology, Columbia College Chicago;
- Believes that good design comes from heart and limitless imagination;
- Fan of Dan Brown, loves sci-fi, mom of 3 cats.

## ISSAC CHEUNG

*Full Stack Developer*



- Over 7 years experience focusing on software development, engineering roles , and mobile applications in gaming and retail application sectors;
- Former Senior Analyst Programmer at Derivco Hong Kong, an online web and mobile game developer;
- Former Software Engineer at Advanced Systems Information Technology, with experience in development of POS and ERP systems;
- Double Degree in Bachelor of Science (Honors) in Computing and Bachelor of Business Administration (Honors) in Management from The Hong Kong Polytechnic University.





# The Team (4)

## ISABELLA LAI

### Senior Director

- Over 12 years of experience in financial industry, as a Senior Director in European banking and wealth management;
- Senior Director at Aeneas group, a technology driven financial services platform based in Hong Kong;
- Former Senior Director at Varengold Hong Kong, wholly owned by Varengold Bank AG, a German Private Bank listed in Hamburg;
- Former senior principal relationship manager at Credit Suisse Privilege, Credit Suisse Banking Group;
- BBA (Fin) from Simon Fraser University, Canada

## ANDY CHAN

### Head of Insurance

- CEO of PIBA Broker (2015 – present);
- Specialized in Property & Casualty Insurance;
- Former Marketing Manager at HWL International Holdings Limited, a member of CIB, focusing on Marketing Planning, Finance & Accounting, Legal Compliance, specialized in Property & Casualty Insurance;
- Former General Manager at Million Trend Limited – General Agent of MetLife Hong Kong;
- Former Agency Manager at MetLife Hong Kong, specializing in team building and sales management for life insurance.
- Extra Curriculum: “Certificate in Fitness Instruction” from Hong Kong Baptist University;

## TEDDY IP

### Senior Director

- Adept executive in financial industry with over 20 years of experience in global banks and corporations;
- Senior Director at Aeneas group, a technology driven financial services platform based in Hong Kong;
- Former International Banking Manager, Citibank Australia;
- Former Project Consultant, Coopers & Lybrand Associates (now known as PWC) in Hong Kong;
- Former General Manger (Investment) of CWC Limited, founded by Jardine Group and Temasek, Singapore for investment in China;
- MBA (CUHK), Master in Environmental Engineering (UNSW, Australia), Master and Bachelor degrees in Social Sciences (HKU)

## AARON REGALA

### Business Analyst

- Blockchain technology investor;
- Formerly worked in retail banking;
- Computing enthusiast building finance analytics;
- Graduated with B Sc. Physics from University College London



# Strategic Advisors & Partners

## PROFESSOR DOUGLAS W. ARNER

*Senior Regulatory and Strategic Advisor*



- Kerry Holdings Professor in Law at the University of Hong Kong ("HKU");
- Director of HKU LLM in Compliance and Regulation;
- Senior Visiting Fellow of Melbourne Law School, University of Melbourne;
- Co-Founder and former Director of the Asian Institute of International Financial Law, Faculty of Law, HKU;
- Leading specialist in economic and financial law, regulation, and development;
- Co-Authored or editor of 15 books including "Reconceptualising Global Finance and its Regulation" (Cambridge, 2016);
- PhD and LLM in banking and finance law from University of London (Queen Mary College).

## DR S.M. YIU

*Advisor*



- Associate Professor in the Department of Computer Science at the University of Hong Kong;
- Research and areas of expertise are computer security, cryptography, bioinformatics;
- Published over 100 papers in journals and conferences - Google Scholar statistics: Citations (8627), h-index (41), i10-index (98);
- Experience in industrial projects with Huawei, Hong Kong Sanatorium & Hospital, Astri, and Bank of China;
- PhD in Computer Science, The University of Hong Kong;
- MS in Computer and Information Science, Temple University (USA);
- BSc in Computer Science, The Chinese University of Hong Kong.

## JEFF MARQUASS

*Advisor*



- Director of HOYA Surgical Optics, a specialist provider of ophthalmologists with high-quality intraocular lenses for use in the treatment of cataracts for over 25 years;
- Former Vice President Business Development at Advanced First Aid Research, a medical device company focused on wound care product development;
- Former Managing Director at Vendor Management Consulting Asia, a boutique consulting firm connecting European medical devices, pharma, biotech, and FMCG companies with Asia;
- Master Business Administration, University of Melbourne.

## JULIAN TING

*Advisor*



- Former General Manager at Innovative Diagnostics, a leading Asian pathology diagnostic group;
- Formerly worked at Grange Partners in Singapore, a family office backed institution focusing on Southeast Asian Private Equity;
- Formerly held positions at HSBC Private Wealth Solutions and ECM Libra Investment Bank;
- Masters in Business Administration (MBA) from Columbia Business School (Dean's Honors); Private Equity Fellow;
- Bachelor of Laws – LLB (Hons) Programme from London School of Economics.



# Strategic Advisors & Partners

## DR JASON CHAN

*Advisor*

- Assistant Professor at the Department of Otorhinolaryngology, Head & Neck Surgery at The Chinese University of Hong Kong;
- Graduated from Guy's, King's and St Thomas' School of Medicine in London;
- Specialist training in Otolaryngology, Head and Neck surgery at the Johns Hopkins School of Medicine with advanced training in Head and Neck Surgery on microvascular reconstruction and robotics;
- ECFMG, MBBS(London), LMCHK, Diplomate American Board of Otolaryngology, Head and Neck Surgery.

## DR SUNNY WONG

*Advisor*

- Assistant Professor in the Department of Medicine and Therapeutics at The Chinese University of Hong Kong;
- Principal investigator at the Li Ka Shing Institute of Health Science, the Institute of Digestive Disease and the State Key Laboratory of Digestive Disease;
- A clinician-scientist with expertise in host-microbe dynamics, in diseases including digestive cancers, mycobacterial and Clostridium difficile infections;
- Published 50+ peer-reviewed papers in top journals, including the New England Journal of Medicine and Nature Genetics;
- Investigator in multi-centered epidemiological studies, phase 2/3 drug trials.

## DR WILLIAM WU

*Advisor*

- Assistant Professor at the Department of Anesthesia and Intensive Care at The Chinese University of Hong Kong;
- Expert in molecular pharmacology and toxicology;
- Has published extensively in cancer biomarker diagnostics and novel therapeutics; Published more than 150 internationally recognized, peer-reviewed articles in top international journals, including Nature Communications, Autophagy, Cell Research, Cancer Research with an h-index of 40, and four book chapters;
- Earned his fellowship in the Royal College of Pathologists (FRCPath), and has been awarded the First-Class Higher Education Outstanding Scientific Research Output Award (Natural Science) by the Ministry of Education of China;
- PhD in Medical Sciences from CUHK and received post-doctoral training in the Institute of Digestive Diseases, CUHK afterwards.

## DR KENNY YU

*Advisor*

- Clinical Research Fellow at the Salford Royal NHS Foundation Trust in the UK;
- PhD at The University of Manchester – Faculty of Medical and Human Sciences – Stem Cell and Neurotherapies Laboratory;
- Key areas of research interests include Cancer Biology, Oncology, Cell Culture, Genetic Engineering, Neurosurgery, and Cancer Immunology;
- Neurosurgeon at The University of Manchester.



# Strategic Advisors & Partners

## DR KWOK KA WAI

*Advisor*

- Assistant Professor in the Department of Mechanical Engineering at The University of Hong Kong;
- Research focuses on image-guided robotic surgeries and their associated master-slave control interfaces;
- PhD from Imperial College London;
- BEng and MPhil degrees in Automation and Computer-Aided Engineering, The Chinese University of Hong Kong;
- Recipient of the Croucher Foundation Fellowship, which currently supported his postdoctoral research jointly hosted by University of Georgia, and Brigham and Women's Hospital - Harvard Medical School.

## JOE HUI

*Advisor*

- Investment Director, Quantitative Strategies, Eagle Eye Group;
- Guest speaker at the Institute for China Business, HKU Space;
- Former quantitative investment consultant roles for Hong Kong and China funds;
- Former Senior Researcher Fellow at the Faculty of Engineering, The University of Hong Kong; Key research interests include quantitative finance, blockchain technologies, and artificial intelligence;
- Master of Business Administration in Finance, jointly offered by The Chinese University of Hong Kong and Tsinghua University (Beijing).

## DR OWEN KO

*Advisor*

- Clinical Lecturer in the Department of Medicine and Therapeutics at The Chinese University of Hong Kong ("CUHK");
- Published two first authored Nature papers and one first authored Nature Neuroscience paper;
- Bachelor of Medicine and Bachelor of Surgery Programme (MBChB) at CUHK in 2005. Bachelor of Medical Sciences (BMedSci) under the mentorship of Professor Wing-ho Yung in the School of Biomedical Sciences;
- PhD programme in Neuroscience at University College London (UCL) under the guidance of Professor Thomas Mrsic-Flogel. His breakthrough research has led to his Runner-up Award of the Eppendorf & Science Prize for Neurobiology as the first awardee in Hong Kong.





# Strategic Advisors & Partners

## VIRGINIA LAM

*Marketing Advisor*

- 15 years of marketing experience in startups-turned-listed-companies; Passion for blockchain innovations;
- Co-Founder of COINS Marketing, a partner for fintech and blockchain projects;
- Head of Marketing at Xbrick, a global crypto currency exchange owned by X Blockchain Pty Ltd, a blockchain technology company headquartered in Sydney, Australia;
- Marketing Lead at The Abyss, a crypto reward ecosystem for gamers and developers;
- Co-Founder of V Partnership, a digital marketing agency;
- Former Marketing Director at Ensogo Limited (ASX: E88), operator of ecommerce businesses across Asia;
- BA – University of Sydney, English and Psychology.



## DOUGLAS CHING

*Marketing Advisor*

- Over 20 years of marketing experience including digital marketing and social media marketing across the ecommerce and consumer electronics industries;
- Co-Founder of two marketing agencies under OOKA Group: Coins Marketing (Token sale consultant agency) and V Partnership (Digital marketing agency);
- Former General Manager at Ensogo Limited (ASX:E88), established China headquarters;
- Qualified Google Analytics Individual; Cisco CCNA; Microsoft MCSE + MCDBA;
- Master of E-Commerce from Middlesex University, United Kingdom;
- BA – Economics, University of Toronto, Canada;



## Strategic Partners

**TVM | CHINA**

**APTORUM**

**ACTICULE**



**Videns**  
Life Sciences

**SIGNATE**

**Summerhill Advisors**



# Contacts

[www.aencoin.com](http://www.aencoin.com)

T: (852) 8199 0918

E: [moon@aencoin.com](mailto:moon@aencoin.com)

## Community:

Telegram:

<https://t.me/AENCO>

[https://t.me/aencoin\\_announcements](https://t.me/aencoin_announcements)

Medium:

[medium.com/@aencoin](https://medium.com/@aencoin)

Twitter:

[twitter.com/AENCOIN](https://twitter.com/AENCOIN)

Facebook:

[www.facebook.com/AENCOIN/](https://www.facebook.com/AENCOIN/)

Discord:

<https://discord.gg/5nTn4rC>

LinkedIn:

<https://www.linkedin.com/company/aenco>

Youtube:

[youtube.aencoin.com](https://youtube.aencoin.com)

